GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

London/Washington, D.C. 06 August 2019 -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials